Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364402 | 0.78 | HDAC8 (0.44) | SMN1; SMN2ALDH1A1POLBGAATP53 | |
| SCHEMBL2432453 | 0.75 | GAA (0.44) | SMN1; SMN2ALDH1A1POLBGAATP53 | |
| SCHEMBL2436660 | 0.75 | GAA (0.44) | SMN1; SMN2ALDH1A1POLBGAATP53 | |
| SCHEMBL17802837 | 0.70 | TP53 (0.47) | SMN1; SMN2ALDH1A1POLBGAATP53 | |
| SCHEMBL14592478 | 0.69 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1POLBGAATP53 | |
| SCHEMBL2435801 | 0.69 | GAA (0.41) | SMN1; SMN2ALDH1A1POLBGAATP53 | |
| SCHEMBL2433765 | 0.69 | GAA (0.41) | SMN1; SMN2ALDH1A1POLBGAATP53 | |
| SCHEMBL17711735 | 0.69 | GAA (0.49) | SMN1; SMN2ALDH1A1POLBGAATP53 | |
| SCHEMBL15382523 | 0.69 | GAA (0.49) | SMN1; SMN2ALDH1A1POLBGAATP53 | |
| SCHEMBL17711734 | 0.69 | GAA (0.49) | SMN1; SMN2ALDH1A1POLBGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | SMN1; SMN2 3702/4885ALDH1A1 981/4885POLB 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.